← Leaderboards
Terry Roemer
Prokaryotics, Inc.
$17,585,712
Attributed
$17,585,712
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.6M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,585,712 · 12
By mechanism
R44$11,252,175 · 5
U19$3,145,250 · 3
R01$2,038,369 · 1
R42$594,918 · 1
R21$555,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseIn VitroResistanceInfectionPharmaceutical PreparationsIn VivoAnalogPathogenBactericideMediatingHepg2AntibioticsAnabolismPathway InteractionsPropertyLeadFormulationHospitalsReportingMulti-Drug ResistanceLifeMortalityBacterial InfectionsScale Up
Grant awards (28)
Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics$996,450
R44 · FY2025 · AI · contact PI
Pre-clinical Safety and Toxicology Studies of a PO-administered b-lactam-tarocin combination agent to treat methicillin susceptible and resistant staphylococci$741,804
U19 · FY2025 · AI · contact PI
Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis$679,683
R01 · FY2025 · AI · contact PI
Development of a first-in-class antifungal agent to treat Candidiasis and Candidemia$668,118
U19 · FY2025 · AI · contact PI
Development of an active site inhibitor of Fks1 as a broad spectrum antifungal agent$299,697
R44 · FY2025 · AI · contact PI
Structure-based design of antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, Mcd4$170,000
R21 · FY2025 · AI · contact PI
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci$974,575
R44 · FY2024 · AI · contact PI
Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis$679,343
R01 · FY2024 · AI · contact PI
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis$295,592
R42 · FY2024 · AI · contact PI
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci$991,117
R44 · FY2023 · AI · contact PI
Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis$679,343
R01 · FY2023 · AI · contact PI
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis$299,326
R42 · FY2023 · AI · contact PI
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections$1,000,000
R44 · FY2022 · AI · contact PI
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci$999,396
R44 · FY2022 · AI · contact PI
Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics$300,000
R44 · FY2022 · AI · contact PI
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections$1,000,000
R44 · FY2021 · AI · contact PI
Novel inhibitors of bacterial cell envelope biogenesis for prophylaxis against carbapenem-resistant Enterobacteriaceae$558,902
U19 · FY2021 · AI · contact PI
Characterization of MsbA inhibitors as potential antibiotic leads to treat carbapenem-resistant Enterobacteriaceae (CRE)$140,000
R21 · FY2021 · AI · contact PI
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci$1,000,000
R44 · FY2020 · AI · contact PI
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae$842,442
R44 · FY2020 · AI · contact PI
Novel inhibitors of bacterial cell envelope biogenesis for prophylaxis against carbapenem-resistant Enterobacteriaceae$576,152
U19 · FY2020 · AI · contact PI
Characterization of MsbA inhibitors as potential antibiotic leads to treat carbapenem-resistant Enterobacteriaceae (CRE)$245,000
R21 · FY2020 · AI · contact PI
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci$1,000,000
R44 · FY2019 · AI · contact PI
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae$952,958
R44 · FY2019 · AI · contact PI
Novel inhibitors of bacterial cell envelope biogenesis for prophylaxis against carbapenem-resistant Enterobacteriaceae$600,274
U19 · FY2019 · AI · contact PI
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections$295,541
R44 · FY2019 · AI · contact PI
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae$300,000
R44 · FY2018 · AI · contact PI
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci$299,999
R44 · FY2018 · AI · contact PI